secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-070337
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics Q1 2025 net loss narrows to $4.1M; cash runway into Q1 2027
--------------------------------------------------------------------------------

- Net loss attributable of $4.1M ($0.02/shr) vs $6.5M ($0.04/shr) in Q1 2024; revenue $1.5M (flat YoY).
- Cash and marketable securities of $47.9M as of Mar 31, 2025 expected to fund operations into Q1 2027.
- OpRegen 36-month data to be presented June 21 at CTS 2025; OPC1 DOSED study initiated Feb 2025 for spinal cord injury.
- 3rd Annual SCI Investor Symposium announced with Christopher & Dana Reeve Foundation, virtual starting June 27, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000095017025070337/0000950170-25-070337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000095017025070337/lctx-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer